Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

NCT07210632 is registered in ClinicalTrials.gov with Eben Rosenthal as lead sponsor.

NCT NCT07210632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07210632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)
Lead sponsor
Eben Rosenthal
Phase
Phase 1
Overall status
Recruiting
Start date
March 27, 2026
Completion date
March 30, 2031
Enrollment
38 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain cancer, glioma, hgg, high grade glioma, high grade glioma (hgg) of the brain with braf aberration, high grade glioma (iii or iv), high grade gliomas